Previous Close | 102.16 |
Open | 99.54 |
Bid | 98.54 x 13500 |
Ask | 98.85 x 54600 |
Day's Range | 98.33 - 101.26 |
52 Week Range | 64.48 - 111.74 |
Volume | |
Avg. Volume | 24,585 |
Market Cap | 250.815B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 46.67 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.